Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.63 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14364629 | 0.87 | MAOB (0.69) | MAOBPARP15PARP14PARP10SCN3A | |
| SCHEMBL28570332 | 0.85 | FFAR1 (0.71) | MAOBFFAR1FFAR4 | |
| SCHEMBL28141293 | 0.83 | AKR1B1 (0.58) | PTPN1FFAR1FFAR4 | |
| SCHEMBL6245446 | 0.83 | NR1H4 (0.47) | MAOBFFAR1FFAR4 | |
| SCHEMBL6237724 | 0.82 | MAOB (0.64) | MAOBFFAR1FFAR4 | |
| SCHEMBL2552269 | 0.82 | FOLH1 (0.53) | PTPN1FFAR1FFAR4 | |
| SCHEMBL1444784 | 0.81 | MAOB (0.75) | MAOBPARP15PARP14PARP10SCN3A | |
| SCHEMBL6239017 | 0.81 | FFAR1 (0.51) | MAOBPTPN1FFAR1FFAR4 | |
| SCHEMBL4759812 | 0.81 | MAOB (0.65) | MAOBFFAR1FFAR4 | |
| SCHEMBL6241283 | 0.81 | FFAR4 (0.78) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | MAOB 3606/4885PARP15 1336/4885PARP14 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.